Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cisplatin + Gemcitabine + Pembrolizumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
| Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
| Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, PMBL, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-positive NSCLC, esophageal SCC, cervical cancer, HNSCC, and TNBC, in combination with platnum-based chemo in NSCLC, with pemetrexed and platinum in pleural mesothelioma and non-sNSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in sNSCLC, with axitinib or lenvatinib in RCC, with lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, with platinum and fluoropyrimidine-based chemo for esophageal or gastroesophageal carcinoma, with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemo for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, with fluoropyrimidine- and platinum-containing chemo for HER2-negative gastric or GEJ adenocarcinoma, with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-positive cervical cancer, with gemcitabine and cisplatin for biliary tract cancer, with chemoradiation for cervical cancer, with carboplatin and paclitaxel for endometrial carcinoma, with paclitaxel with or without bevacizumab for epithelial ovarian, Fallopian tube, and peritonium cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03425643 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | Active, not recruiting | USA | ROU | POL | LVA | LTU | ITA | IRL | GBR | FRA | EST | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
| NCT03260712 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab in Biliary Tract Cancer | Completed | GBR | ESP | DEU | 0 |
| NCT06312137 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (TroFuse-019) | Recruiting | USA | TUR | ROU | POL | NZL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT06788912 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Gemcitabine + Pembrolizumab Pembrolizumab + Sacituzumab govitecan-hziy Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) | Recruiting | USA | TUR | POL | ITA | HUN | GRC | ESP | 2 |
| NCT04003636 | Phase III | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) | Completed | USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
| NCT06632327 | Phase III | Docetaxel + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pembrolizumab + Vinorelbine Carboplatin + Nivolumab + Vinorelbine Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Gemcitabine Docetaxel + Gemcitabine Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Atezolizumab + Cisplatin + Vinorelbine Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Vinorelbine Atezolizumab + Docetaxel + Gemcitabine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine + Nivolumab Atezolizumab Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Vinorelbine Docetaxel + Gemcitabine + Pembrolizumab Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Vinorelbine Cisplatin + Pembrolizumab + Vinorelbine Atezolizumab + Carboplatin + Pemetrexed Disodium | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT06282575 | Phase III | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + Zanidatamab Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + Zanidatamab Cisplatin + Gemcitabine + Zanidatamab | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Recruiting | USA | TUR | SWE | ROU | ITA | ISR | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | ARG | 9 |
| NCT05967182 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
| NCT02608684 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Completed | USA | 0 |
| NCT02690558 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | Active, not recruiting | USA | 0 |
| NCT06001658 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers | Recruiting | USA | 0 |
| NCT06923475 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma (NEODISCO) | Not yet recruiting | NLD | 0 |
| NCT03924856 | Phase III | Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Gemcitabine | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866) | Active, not recruiting | USA | TUR | SWE | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 6 |
| NCT04267848 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Recruiting | USA | 1 |
CKB BOOST